Vertex Pharmaceuticals Inc

자세한 내용은 Vertex Pharmaceuticals Inc 회사

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

회사 정보

종목 코드 VRTX

회사 이름Vertex Pharmaceuticals Inc

상장일Jul 24, 1991

CEODr. Reshma Kewalramani

직원 수6100

유형Ordinary Share

회계 연도 종료Jul 24

주소50 Northern Avenue

도시BOSTON

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02210

전화16173416393

웹사이트https://www.vrtx.com/

종목 코드 VRTX

상장일Jul 24, 1991

CEODr. Reshma Kewalramani

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.83K

+8.93%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

이름

이름/직위

직위

주식 보유

변동

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

사업별USD

이름

수익

비율

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

지역별USD

이름

수익

비율

United States

1.65B

59.91%

Europe

826.60M

29.95%

Other

280.10M

10.15%

사업별

지역별

사업별USD

이름

수익

비율

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

주식 보유 통계

마지막 업데이트: Thu, May 15

주주

주주 유형

주주

비율

Capital World Investors

11.13%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

5.67%

BlackRock Institutional Trust Company, N.A.

5.46%

State Street Global Advisors (US)

4.60%

Other

63.84%

주주

비율

Capital World Investors

11.13%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

5.67%

BlackRock Institutional Trust Company, N.A.

5.46%

State Street Global Advisors (US)

4.60%

Other

63.84%

주주 유형

주주

비율

Investment Advisor

59.80%

Investment Advisor/Hedge Fund

28.63%

Research Firm

2.54%

Pension Fund

2.42%

Bank and Trust

2.05%

Sovereign Wealth Fund

1.44%

Hedge Fund

1.30%

Insurance Company

0.16%

Individual Investor

0.14%

Other

1.51%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Capital World Investors

28.53M

11.11%

+207.61K

+0.73%

Mar 31, 2025

The Vanguard Group, Inc.

23.38M

9.1%

+232.41K

+1.00%

Mar 31, 2025

Capital Research Global Investors

14.54M

5.66%

+4.11M

+39.38%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

14.00M

5.45%

-330.35K

-2.31%

Mar 31, 2025

State Street Global Advisors (US)

11.79M

4.59%

-190.75K

-1.59%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.62M

2.97%

-1.49M

-16.32%

Mar 31, 2025

Jennison Associates LLC

5.06M

1.97%

+744.68K

+17.25%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.76M

2.24%

+113.52K

+2.01%

Mar 31, 2025

Wellington Management Company, LLP

5.45M

2.12%

-461.34K

-7.80%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

5.31M

2.07%

-20.76K

-0.39%

Jun 30, 2025

383.100USD

Vertex Pharmaceuticals Inc

383.100

개요

회사

금융